Toremifene for Reduction of fractures and other Estrogen deficiency side effects in men on Androgen deprivation Therapy 2.

Trial Profile

Toremifene for Reduction of fractures and other Estrogen deficiency side effects in men on Androgen deprivation Therapy 2.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2013

At a glance

  • Drugs Toremifene (Primary)
  • Indications Fracture; Male osteoporosis; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TREAT-2
  • Sponsors GTx
  • Most Recent Events

    • 09 May 2011 Status changed from not yet recruiting to withdrawn prior to recruitment - trial withdrawn prior to recruitment prior to enrolment
    • 05 Oct 2010 Additional lead trial centre, investigator trial sponser identified as reported by ClinicalTrials.gov.
    • 05 Oct 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top